Go Pro
→ If you keep cash in a U.S. bank account… read this NOW (From Banyan Hill Publishing) (Ad)tc pixel Free TNDM Stock Alerts

Tandem Diabetes Care (TNDM) Competitors

Tandem Diabetes Care logo
$16.50 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$16.62 +0.12 (+0.72%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

TNDM vs. LIVN, ITGR, PLSE, IRTC, and TMDX

Should you buy Tandem Diabetes Care stock or one of its competitors? Tandem Diabetes Care's main competitors and comparable companies include LivaNova (LIVN), Integer (ITGR), Pulse Biosciences (PLSE), iRhythm Technologies (IRTC), and TransMedics Group (TMDX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Tandem Diabetes Care compare to LivaNova?

Tandem Diabetes Care (NASDAQ:TNDM) and LivaNova (NASDAQ:LIVN) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations.

97.6% of LivaNova shares are owned by institutional investors. 2.1% of Tandem Diabetes Care shares are owned by insiders. Comparatively, 0.4% of LivaNova shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

LivaNova has a net margin of 12.82% compared to Tandem Diabetes Care's net margin of -6.08%. LivaNova's return on equity of 16.35% beat Tandem Diabetes Care's return on equity.

Company Net Margins Return on Equity Return on Assets
Tandem Diabetes Care-6.08% -45.97% -6.23%
LivaNova 12.82%16.35%7.76%

Tandem Diabetes Care presently has a consensus target price of $29.13, suggesting a potential upside of 72.61%. LivaNova has a consensus target price of $84.13, suggesting a potential upside of 10.94%. Given Tandem Diabetes Care's higher possible upside, equities analysts plainly believe Tandem Diabetes Care is more favorable than LivaNova.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tandem Diabetes Care
1 Sell rating(s)
11 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.48
LivaNova
0 Sell rating(s)
5 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.55

In the previous week, Tandem Diabetes Care had 11 more articles in the media than LivaNova. MarketBeat recorded 11 mentions for Tandem Diabetes Care and 0 mentions for LivaNova. LivaNova's average media sentiment score of 0.75 beat Tandem Diabetes Care's score of 0.57 indicating that LivaNova is being referred to more favorably in the news media.

Company Overall Sentiment
Tandem Diabetes Care Positive
LivaNova Positive

Tandem Diabetes Care has a beta of 1.66, suggesting that its share price is 66% more volatile than the broader market. Comparatively, LivaNova has a beta of 0.87, suggesting that its share price is 13% less volatile than the broader market.

Tandem Diabetes Care has higher earnings, but lower revenue than LivaNova. Tandem Diabetes Care is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tandem Diabetes Care$1.01B1.16-$204.71M-$0.93N/A
LivaNova$1.39B3.01-$242.47M$3.3822.43

Summary

LivaNova beats Tandem Diabetes Care on 10 of the 17 factors compared between the two stocks.

How does Tandem Diabetes Care compare to Integer?

Integer (NYSE:ITGR) and Tandem Diabetes Care (NASDAQ:TNDM) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, dividends, valuation, earnings, profitability and analyst recommendations.

In the previous week, Tandem Diabetes Care had 6 more articles in the media than Integer. MarketBeat recorded 11 mentions for Tandem Diabetes Care and 5 mentions for Integer. Tandem Diabetes Care's average media sentiment score of 0.57 beat Integer's score of 0.27 indicating that Tandem Diabetes Care is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Integer
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
Tandem Diabetes Care
3 Very Positive mention(s)
6 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Integer has a beta of 0.58, suggesting that its share price is 42% less volatile than the broader market. Comparatively, Tandem Diabetes Care has a beta of 1.66, suggesting that its share price is 66% more volatile than the broader market.

Integer currently has a consensus target price of $109.86, suggesting a potential downside of 13.14%. Tandem Diabetes Care has a consensus target price of $29.13, suggesting a potential upside of 72.61%. Given Tandem Diabetes Care's stronger consensus rating and higher probable upside, analysts plainly believe Tandem Diabetes Care is more favorable than Integer.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Integer
0 Sell rating(s)
13 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.07
Tandem Diabetes Care
1 Sell rating(s)
11 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.48

Integer has higher revenue and earnings than Tandem Diabetes Care. Tandem Diabetes Care is trading at a lower price-to-earnings ratio than Integer, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Integer$1.85B2.32$102.81M$3.6634.56
Tandem Diabetes Care$1.01B1.16-$204.71M-$0.93N/A

99.3% of Integer shares are held by institutional investors. 1.1% of Integer shares are held by insiders. Comparatively, 2.1% of Tandem Diabetes Care shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Integer has a net margin of 6.97% compared to Tandem Diabetes Care's net margin of -6.08%. Integer's return on equity of 12.79% beat Tandem Diabetes Care's return on equity.

Company Net Margins Return on Equity Return on Assets
Integer6.97% 12.79% 6.48%
Tandem Diabetes Care -6.08%-45.97%-6.23%

Summary

Integer beats Tandem Diabetes Care on 9 of the 17 factors compared between the two stocks.

How does Tandem Diabetes Care compare to Pulse Biosciences?

Tandem Diabetes Care (NASDAQ:TNDM) and Pulse Biosciences (NASDAQ:PLSE) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, media sentiment, profitability, earnings, valuation, dividends and analyst recommendations.

Tandem Diabetes Care currently has a consensus price target of $29.13, indicating a potential upside of 72.61%. Pulse Biosciences has a consensus price target of $50.20, indicating a potential upside of 2.33%. Given Tandem Diabetes Care's higher probable upside, equities analysts clearly believe Tandem Diabetes Care is more favorable than Pulse Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tandem Diabetes Care
1 Sell rating(s)
11 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.48
Pulse Biosciences
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.86

Tandem Diabetes Care has a beta of 1.66, suggesting that its stock price is 66% more volatile than the broader market. Comparatively, Pulse Biosciences has a beta of 1.57, suggesting that its stock price is 57% more volatile than the broader market.

Pulse Biosciences has lower revenue, but higher earnings than Tandem Diabetes Care. Pulse Biosciences is trading at a lower price-to-earnings ratio than Tandem Diabetes Care, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tandem Diabetes Care$1.01B1.16-$204.71M-$0.93N/A
Pulse Biosciences$350K9,923.13-$72.78M-$1.18N/A

Tandem Diabetes Care has a net margin of -6.08% compared to Pulse Biosciences' net margin of -6,755.78%. Tandem Diabetes Care's return on equity of -45.97% beat Pulse Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Tandem Diabetes Care-6.08% -45.97% -6.23%
Pulse Biosciences -6,755.78%-94.42%-79.96%

In the previous week, Tandem Diabetes Care had 8 more articles in the media than Pulse Biosciences. MarketBeat recorded 11 mentions for Tandem Diabetes Care and 3 mentions for Pulse Biosciences. Tandem Diabetes Care's average media sentiment score of 0.57 beat Pulse Biosciences' score of 0.44 indicating that Tandem Diabetes Care is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Tandem Diabetes Care
3 Very Positive mention(s)
6 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Pulse Biosciences
0 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

77.0% of Pulse Biosciences shares are owned by institutional investors. 2.1% of Tandem Diabetes Care shares are owned by insiders. Comparatively, 74.0% of Pulse Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Tandem Diabetes Care beats Pulse Biosciences on 11 of the 16 factors compared between the two stocks.

How does Tandem Diabetes Care compare to iRhythm Technologies?

iRhythm Technologies (NASDAQ:IRTC) and Tandem Diabetes Care (NASDAQ:TNDM) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, institutional ownership, valuation, risk, dividends and media sentiment.

iRhythm Technologies has a net margin of -1.69% compared to Tandem Diabetes Care's net margin of -6.08%. iRhythm Technologies' return on equity of 10.11% beat Tandem Diabetes Care's return on equity.

Company Net Margins Return on Equity Return on Assets
iRhythm Technologies-1.69% 10.11% 1.53%
Tandem Diabetes Care -6.08%-45.97%-6.23%

iRhythm Technologies has higher earnings, but lower revenue than Tandem Diabetes Care. iRhythm Technologies is trading at a lower price-to-earnings ratio than Tandem Diabetes Care, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
iRhythm Technologies$747.14M4.87-$44.55M-$0.43N/A
Tandem Diabetes Care$1.01B1.16-$204.71M-$0.93N/A

iRhythm Technologies has a beta of 1.45, indicating that its stock price is 45% more volatile than the broader market. Comparatively, Tandem Diabetes Care has a beta of 1.66, indicating that its stock price is 66% more volatile than the broader market.

iRhythm Technologies currently has a consensus target price of $179.93, suggesting a potential upside of 63.00%. Tandem Diabetes Care has a consensus target price of $29.13, suggesting a potential upside of 72.61%. Given Tandem Diabetes Care's higher probable upside, analysts clearly believe Tandem Diabetes Care is more favorable than iRhythm Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
iRhythm Technologies
1 Sell rating(s)
1 Hold rating(s)
12 Buy rating(s)
2 Strong Buy rating(s)
2.94
Tandem Diabetes Care
1 Sell rating(s)
11 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.48

In the previous week, Tandem Diabetes Care had 4 more articles in the media than iRhythm Technologies. MarketBeat recorded 11 mentions for Tandem Diabetes Care and 7 mentions for iRhythm Technologies. Tandem Diabetes Care's average media sentiment score of 0.57 beat iRhythm Technologies' score of 0.15 indicating that Tandem Diabetes Care is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
iRhythm Technologies
1 Very Positive mention(s)
0 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Tandem Diabetes Care
3 Very Positive mention(s)
6 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

iRhythm Technologies beats Tandem Diabetes Care on 9 of the 15 factors compared between the two stocks.

How does Tandem Diabetes Care compare to TransMedics Group?

Tandem Diabetes Care (NASDAQ:TNDM) and TransMedics Group (NASDAQ:TMDX) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, earnings, valuation, institutional ownership and media sentiment.

Tandem Diabetes Care presently has a consensus price target of $29.13, indicating a potential upside of 72.61%. TransMedics Group has a consensus price target of $121.10, indicating a potential upside of 56.02%. Given Tandem Diabetes Care's stronger consensus rating and higher probable upside, analysts clearly believe Tandem Diabetes Care is more favorable than TransMedics Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tandem Diabetes Care
1 Sell rating(s)
11 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.48
TransMedics Group
1 Sell rating(s)
6 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.33

Tandem Diabetes Care has a beta of 1.66, suggesting that its stock price is 66% more volatile than the broader market. Comparatively, TransMedics Group has a beta of 1.94, suggesting that its stock price is 94% more volatile than the broader market.

TransMedics Group has lower revenue, but higher earnings than Tandem Diabetes Care. Tandem Diabetes Care is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tandem Diabetes Care$1.01B1.16-$204.71M-$0.93N/A
TransMedics Group$605.49M4.43$190.29M$3.8919.95

99.7% of TransMedics Group shares are owned by institutional investors. 2.1% of Tandem Diabetes Care shares are owned by company insiders. Comparatively, 6.9% of TransMedics Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Tandem Diabetes Care had 2 more articles in the media than TransMedics Group. MarketBeat recorded 11 mentions for Tandem Diabetes Care and 9 mentions for TransMedics Group. Tandem Diabetes Care's average media sentiment score of 0.57 beat TransMedics Group's score of 0.36 indicating that Tandem Diabetes Care is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Tandem Diabetes Care
3 Very Positive mention(s)
6 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
TransMedics Group
1 Very Positive mention(s)
2 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

TransMedics Group has a net margin of 22.69% compared to Tandem Diabetes Care's net margin of -6.08%. TransMedics Group's return on equity of 15.88% beat Tandem Diabetes Care's return on equity.

Company Net Margins Return on Equity Return on Assets
Tandem Diabetes Care-6.08% -45.97% -6.23%
TransMedics Group 22.69%15.88%5.95%

Summary

TransMedics Group beats Tandem Diabetes Care on 10 of the 17 factors compared between the two stocks.

Get Tandem Diabetes Care News Delivered to You Automatically

Sign up to receive the latest news and ratings for TNDM and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TNDM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TNDM vs. The Competition

Export
MetricTandem Diabetes CareHealthcare Equipment & Supplies IndustryHealthcare SectorNASDAQ Exchange
Market Cap$1.15B$5.48B$7.14B$13.10B
Dividend YieldN/A1.81%2.54%16.76%
P/E Ratio-17.7424.55273.6726.04
Price / Sales1.1367.76611.8291.49
Price / CashN/A32.4377.6051.75
Price / Book7.215.6810.926.30
Net Income-$204.71M$152.11M$3.50B$361.43M
7 Day Performance4.96%-2.01%-2.11%-1.67%
1 Month Performance-19.75%-5.42%-6.34%-3.94%
1 Year Performance25.86%2.75%8.81%2.77%

Tandem Diabetes Care Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TNDM
Tandem Diabetes Care
2.3412 of 5 stars		$16.50
flat		$29.13
+76.6%		+33.0%$1.15B$1.01BN/A2,500
LIVN
LivaNova
3.0494 of 5 stars		$78.17
+0.2%		$84.13
+7.6%		+47.6%$4.30B$1.39B23.133,300
ITGR
Integer
2.2633 of 5 stars		$126.42
+0.1%		$109.86
-13.1%		+22.8%$4.29B$1.85B34.5411,000
PLSE
Pulse Biosciences
2.2061 of 5 stars		$53.31
-1.0%		$45.25
-15.1%		+175.0%$3.81B$350KN/A116
IRTC
iRhythm Technologies
3.4346 of 5 stars		$110.38
+1.0%		$179.93
+63.0%		-33.7%$3.60B$747.14MN/A2,400

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:TNDM) was last updated on 10/2/2026 by MarketBeat.com Staff.
From Our Partners
Elon Warns "America Will Go Bankrupt". Trump's Plan Inside.
National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt with...
American Hartford Gold | Sponsoredtc pixel
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...
Porter & Company | Sponsoredtc pixel
How options let you do more with less capital
Would you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...
Base Camp Trading | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
WATCH THIS BEFORE DECEMBER 8th!!
James Altucher says a quiet government filing could reveal Elon Musk's biggest move yet, and almost nobody has...
Paradigm Press | Sponsoredtc pixel
How Elon’s Empire Ends (and how to profit)
Marc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg termi...
Chaikin Analytics | Sponsoredtc pixel
Bank of America: 'Digital Dollar Inevitable'
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...
Decentralized Masters | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel